The ASC4FIRST trial has shown asciminib, a novel BCR::ABL1 inhibitor, as a promising alternative to current tyrosine kinase inhibitors (TKIs) for chronic phase (CP) chronic myeloid leukaemia (CML).

Australia has committed up to $600 million over a decade to bolster PNG's pitch to secure a team in the competition, with the NRL set to make a final decision in coming weeks. But the ABC revealed ...